The title compound, C 12 H 9 N 3 O, is an intermediate in the synthesis of the muscarinic M2 receptor antagonist AFDX-384. The seven-membered ring adopts a boat conformation and the dihedral angle between the planes of the aromatic rings is 41.51 (9) . In the crystal, molecules are linked into [001] chains of alternating inversion dimers formed by pairs of N-HÁ Á ÁO hydrogen bonds and pairs of N-HÁ Á ÁN hydrogen bonds. In both cases, R 2 2 (8) loops are generated.
Related literature
For the synthesis of the title compound, see: Holzgrabe & Heller (2003) . For the biological activity of substituted 5,11-dihydropyrido [2,3-b] [1,4]benzodiazepin-6-ones, see: Mohr et al. (2004) ; Tahtaoui et al. (2004) . Table 1 Hydrogen-bond geometry (Å , ).
Experimental

Crystal data
Data collection: APEX2 (Bruker, 2013 ); cell refinement: SAINT (Bruker, 2013) 
S1. Experimental
The title compound was synthesized as previously reported (Holzgrabe & Heller, 2003) and recrystallized from methanol-toluene.
S2. Refinement
The N-and C-bound H atoms were included in calculated positions and refined as riding: N2-H = 0.86 Å, C-H and N3
-H = 0.93 Å with U iso (H) = 1.2U eq (C). Special details Experimental. Absorption correctiuon: SADABS-2012/1 (Bruker,2012) was used for absorption correction. wR2(int) was 0.0475 before and 0.0419 after correction. The Ratio of minimum to maximum transmission is 0.9367. The λ/2 correction factor is 0.0015. Symmetry codes: (i) −x+1, −y+1, −z+1; (ii) −x+1, −y+1, −z+2.
